Sensyne Health Plc collaborates with Bristol Myers Squibb. | Kalkine Market Update UK |

October 23, 2020 09:03 PM AEDT | By Team Kalkine Media

Google News:

Recent News

"Aptos EXPO Memorial Stamp Rally" Goes Live in Celebration of Expo 202...

MEXC Unveils New Launchpad Featuring BTC to Kick Off BTC Trading Month

PolicyStreet Launches Flash Sale to Help Malaysians Manage Car Costs A...

Chula-Harvard Collaboration Marks a Milestone in Globalizing Thai Inte...

Sensyne Health Plc (LON:SENS) has entered a research collaboration agreement with Bristol Myers Squibb. The collaboration for which no financial terms have been disclosed will focus on applying the company’s proprietary machine learning to conduct research into disease progression and patient stratification for patients with varied diseases within the broader group of MPNs (Myeloproliferative Neoplasms).

* Evgen Pharma Plc receives all approval for STAR trial

Evgen Pharma Plc (LON:EVG) has received all the necessary regulatory approvals for the SFX-01 treatment for Acute Respiratory Infections, also known as the STAR trial. It is a Phase II/III trial to explore whether the company's lead asset, SFX-01, can decrease the severity, or stop the onset of, ARDS (acute respiratory distress syndrome) in patients with suspected COVID-19.

Greencoat Renewables Plc acquires An Cnoc Wind Farm

Greencoat Renewables Plc (LON:GRP) has acquired An Cnoc Wind Farm located in County Tipperary, Ireland. The acquisition of the 11.5MW wind farm is being funded by the company's existing credit facility, and the total borrowings after the deal would represent 45 percent of Gross Asset Value.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.